View in EDS

A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors.

Saved in:
Bibliographic Details
Title: A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors.
Authors: Koyama T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Yonemori K; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Sato J; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Katsuya Y; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Okada M; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Yoshida T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Okano F; Toray Industries, Inc., New Frontiers Research Laboratories and New Projects Development Division, Kamakura, Kanagawa, Japan., Yamamoto N; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan. nbryamam@ncc.go.jp.
Source: Investigational new drugs [Invest New Drugs] 2026 Apr 14. Date of Electronic Publication: 2026 Apr 14.
Publication Type: Journal Article
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41979863
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Koyama+T%22">Koyama T</searchLink>; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Yonemori+K%22">Yonemori K</searchLink>; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Sato+J%22">Sato J</searchLink>; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Katsuya+Y%22">Katsuya Y</searchLink>; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Okada+M%22">Okada M</searchLink>; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Yoshida+T%22">Yoshida T</searchLink>; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Okano+F%22">Okano F</searchLink>; Toray Industries, Inc., New Frontiers Research Laboratories and New Projects Development Division, Kamakura, Kanagawa, Japan.<br /><searchLink fieldCode="AU" term="%22Yamamoto+N%22">Yamamoto N</searchLink>; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan. nbryamam@ncc.go.jp.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309330%22">Investigational new drugs</searchLink> [Invest New Drugs] 2026 Apr 14. <i>Date of Electronic Publication: </i>2026 Apr 14.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309330 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-0646 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676997%22">01676997 </searchLink><i>NLM ISO Abbreviation: </i>Invest New Drugs <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41979863
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10637-026-01609-z
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Koyama T
      – PersonEntity:
          Name:
            NameFull: Yonemori K
      – PersonEntity:
          Name:
            NameFull: Sato J
      – PersonEntity:
          Name:
            NameFull: Katsuya Y
      – PersonEntity:
          Name:
            NameFull: Okada M
      – PersonEntity:
          Name:
            NameFull: Yoshida T
      – PersonEntity:
          Name:
            NameFull: Okano F
      – PersonEntity:
          Name:
            NameFull: Yamamoto N
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 14
              M: 04
              Text: 2026 Apr 14
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1573-0646
          Titles:
            – TitleFull: Investigational new drugs
              Type: main
ResultId 1